#coronavirus and copd

[drnishthasingh]

Dr. Nishtha Singh is an experienced Chest Specialist and Pulmonologist in Jaipur at Asthma Bhawan with special interests in respiratory medicine, critical care, and sleep medicine. Dr. Nishtha Singh offers complete diagnostic and treatment of all Respiratory conditions, including Tuberculosis, Allergy, Asthma, Lung Cancer, and SLEEP APNEA. Make an appointment with the best doctor or call us: at +91 946 1685 766 and get more information. Read this article to know more about coronavirus and COPD.

[covid-safer-hotties]

Unvaccinated were twice as likely to die from Covid as vaccinated: Nivel - Published Sept 2, 2024

In 2021 and 2022, COVID-19 was twice as likely to be the cause of death of unvaccinated people as in vaccinated people, according to a new study by Nivel. The side-effects center believes the COVID-19 high vaccination rate prevented many deaths, especially in vulnerable groups.

Nivel studied the excess mortality in the Netherlands in pandemic years 2021 and 2022 among people who got vaccinated against the coronavirus, and those who chose not to. The researchers took account of a large number of characteristics that could be associated with death, including age, medical history, migration background, and possible vulnerability to the disease.

The mortality rate among vaccinated people was much lower than expected in the first three months and then the first twelve months after their first vaccination. “There were up to 45 percent fewer deaths than expected based on data on population characteristics and deaths from 2015 to 2018,” Nivel said. It added that other coronavirus measures, like lockdowns and social distancing, also likely played a role in this under-mortality.

These measures also played a role for unvaccinated people. However, the excess mortality in this group was massive. “There were almost three times as many deaths as expected,” Nivel said. Among unvaccinated vulnerable groups - the elderly, people with diabetes, people with COPD, and people with cardiovascular diseases - the excess mortality was up to five times higher than in vaccinated vulnerable groups.

“The observation that in the same period (2021-2022) - a period in which the same COVID-19 measures applied to everyone - there was excess mortality among unvaccinated people and under-mortality among vaccinated people suggest that the COVID-19 vaccination has worked and prevented deaths,” the side effects center said.

[bunnywip]

𝘼-𝙕 𝙇𝙄𝙎𝙏 𝙊𝙁 𝘿𝙄𝙎𝙀𝘼𝙎𝙀𝙎/𝙄𝙇𝙇𝙉𝙀𝙎𝙎𝙀𝙎 𝙁𝙊𝙍 𝙎𝙄𝘾𝙆𝙁𝙄𝘾/𝙒𝙃𝙐𝙈𝙋

— A

Anemia.

Adenomyosis.

Asthma.

Arterial thrombosis.

Allergies.

Anxiety.

Angel toxicosis ( fictional ).

Acne.

Anorexia nervosa.

Anthrax.

Atma virus ( fictional ).

ADHD.

Agoraphobia.

Astrocytoma.

AIDS.

— B

Breast cancer.

Bunions.

Borderline personality disorder.

Botulism.

Barrett's esophagus.

Bowel polyps.

Brucellosis.

Bipolar disorder.

Bronchitis.

Bacterial vaginosis.

Binge eating disorder.

— C

Crohn's disease.

Conjunctivitis.

Coronavirus disease.

Coeliac disease.

Chronic migranes.

Coup.

Cushing syndrome.

Cystic fibrosis.

Cellulitis.

Coma.

Cooties  ( fictional ).

COPD.

Chickenpox.

Cholera.

Cerebral palsy.

Chlamydia.

Constipation.

Cancer.

Common cold.

Chronic pain.

— D

Diabetes.

Dyslexia.

Dissociative identify disorder.

Dengue fever.

Delirium.

Deep vein thrombosis.

Dementia.

Dysthimia.

Diphtheria.

Diarrhoea.

Disruptive mood dysregulation disorder.

Dyspraxia.

Dehydration.

— E

Ebola.

Endometriosis.

Epilepsy.

E-coli.

Ectopic pregnancy.

Enuresis.

Erectile dysfunction.

Exzema.

— F

Fusobacterium infection.

Filariasis.

Fibromyalgia.

Fascioliasis.

Fever.

Food poisoning.

Fatal familial insomnia.

— G

Gonorrhoea.

Ganser syndrome.

Gas gangrene.

Giardiasis.

Gastroesophageal reflux disease.

Gall stones.

Glandular fever.

Greyscale ( fictional ).

Glanders.

— H

Hookworm infection.

Hand, foot and mouth disease.

Hypoglycaemia.

Herpes.

Headache.

Hanahaki disease ( fictional ).

Hyperhidrosis.

Heat stroke.

Heat exhaustion.

Heart failure.

High blood pressure.

Human papillomavirus infection.

Hypersomnia.

HIV.

Heart failure.

Hay fever.

Hepatitis.

Hemorrhoids.

— I

Influenza.

Iron deficiency anemia.

Indigestion.

Inflammatory bowel disease.

Insomnia.

Irritable bowel syndrome.

Intercranial hypertension.

Impetigo.

— K

Keratitis.

Kidney stones.

Kidney infection.

Kawasaki disease.

Kaposi's sarcoma.

— L

Lyme disease.

Lassa fever.

Low blood pressure.

Lupus.

Lactose intolerance.

Lymphatic filariasis.

Leprosy.

— M

Measles.

Mad cow disease.

Mumps.

Major depressive disorder.

Malaria.

Malnutrition.

Motor neurone disease.

Mutism.

Mouth ulcer.

Monkeypox.

Multiple sclerosis.

Meningitis.

Menopause.

Mycetoma.

— N

Norovirus.

Nipah virus infection.

Narcolepsy.

Nosebleed.

Nocardiosis.

— O

Obsessive-compulsive disorder.

Osteoporosis.

Ovarian cyst.

Overactive thyroid.

Oral thrush.

Otitis externa.

— P

Pancreatic cancer.

Pneumonia.

Pelvic inflammatory disease.

PICA.

Premenstrual dysphoric disorder.

Psoriasis.

Parkinson's disease.

Panic disorder.

Polycystic ovarian syndrome.

Plague.

Postpartum depression.

Pediculosis capitis.

Psychosis.

Post-traumatic stress disorder.

— Q

Q fever.

Quintan fever.

— R

Rubella.

Rabbit fever.

Rotavirus infection.

Ringworm.

Restless legs syndrome.

Rhinovirus infection.

Rosacea.

Relapsing fever.

Rheumatoid arthritis.

Rabies.

— S

Shingles.

Sore throat.

Stutter.

Separation anxiety disorder.

Smallpox.

Scoliosis.

Septic shock.

Shigellosis.

Sepsis.

Social anxiety disorder.

Stroke.

Scarlet fever.

Schizophrenia.

Sleep apnea.

Sun burn.

Syphilis.

Sickle cell disease.

Scabies.

Selective mutism.

Salmonella.

Sensory processing disorder.

— T

Thyroid cancer.

Tuberculosis.

Thirst.

Trichuriasis.

Tinea pedis.

Tourette's syndrome.

Trachoma.

Tetanus.

Toxic shock syndrome.

Tinnitus.

Thyroid disease.

Typhus fever.

Tonsillitis.

Thrush.

— U

Urinary tract infection.

Underactive thyroid.

— V

Valley fever.

Vertigo.

Vomiting.

— W

White piedra.

Withdrawal.

Whooping cough.

West nile fever.

— X

Xerophthalmia.

— Y

Yersiniosis.

Yellow fever.

— Z

Zygomycosis.

Zika fever.

Zeaspora.

[colinwilson11]

Medical Suction Devices Market Primed For Growth Due To Rising Prevalence Of Chronic Diseases

The medical suction devices market refers to devices used in healthcare facilities for removing secretions, sputum and other fluids from airways of patients. These devices find widespread applications across emergency care, surgery and in-patient settings.

Medical suction devices include Ac-powered devices, battery-powered devices and dual-powered devices. They are used in various procedures such as respiratory care, gastroenterology, urology, thoracic and liposuction surgeries. Growing prevalence of respiratory diseases such as asthma and Chronic Obstructive Pulmonary Disease (COPD) is a key factor driving the demand for medical suction devices. According to WHO, 65 million people suffer from moderate to severe COPD worldwide.

The Medical Suction Devices Market is estimated to be valued at US$ 1.41 Bn in 2024 and is expected to exhibit a CAGR of 5.2% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the medical suction devices are Olympus, Laerdal Medical, Medela AG, Precision Medical, Inc.,ATMOS Medizin Techni GmbH & Co. KG. These players are focusing on new product launches and partnerships to consolidate their market position.

The growing incidence of respiratory diseases, surgical procedures and trauma/injury cases is fueling the demand for medical suction devices globally. According to WHO, road accidents claim around 1.3 million lives each year. This is prompting increased adoption of these devices in emergency care settings.

Technological advancements are aiding capabilities of suction devices. New devices offer features like adjustable suction pressure, battery longevity, quiet operation, durability and portability. This is making them useful for home healthcare as well as ambulance services.

Market Trends

- Increased demand for portable and standalone devices: Lightweight and wireless medical suction devices are gaining traction as they offer mobility within healthcare facilities as well as in transport vehicles.

- Adoption of IoT enabled devices: Integration of Internet of Things (IoT) enables device monitoring, remote management and predictive maintenance of medical suction devices. This helps improve efficiency.

Market Opportunities

- Growth in home healthcare: Rising preference for home treatment is augmenting demand for small, rechargeable suction devices for home use.

- Emerging markets: Markets in Asia Pacific and Latin America are expected to provide high growth opportunities owing to increasing healthcare spending and large patient pools in these regions.

Impact Of COVID-19 On Medical Suction Devices Market Growth

The COVID-19 pandemic has significantly impacted the growth of the medical suction devices market. The demand for medical suction devices increased sharply during the crisis as they are critical for clearing secretions from airways of COVID-19 infected patients. Pre-COVID, the market was growing at a steady pace due to the rising prevalence of chronic respiratory diseases. However, post the outbreak, requirements surged from hospitals and healthcare facilities worldwide to manage the influx of coronavirus cases. Manufacturers have ramped up production capacities to fulfill the unprecedented demand. Governments across nations also provided incentives to companies and removed barriers to scale operations swiftly. Supply chain disruptions were among major challenges faced initially which impacted timely procurement. With stabilization of situations, steady supplies have been restored, while R&D investments continued towards innovative offerings. Going forward, though demands are expected to remain hightill pandemic subsides, long term growth will be driven by rising incidence of respiratory disorders, aging population and technological advancements. However, high costs remain a limiting factor for widespread adoption in low-income countries.

Geographical Concentration Of Medical Suction Devices Market

In terms of value, North America dominates the medical suction devices market holding over 35% share, led by the US. This is attributed to well-established healthcare infrastructure, heavy funding for medical research and rising rates of chronic illnesses in the region. Additionally, presence of leading manufacturers and willingness to pay for advanced treatments among population have boosted market growth. Europe is the second largest regional market supported by universal healthcare coverage and patient-centric reimbursement systems across major countries. Asia Pacific is poised to be the fastest growing market for medical suction devices in the coming years led by China and India. Factors such as rapidly developing healthcare sectors, rising healthcare spending, growing medical tourism and increasing focus on quality healthcare drive the regional market.

Fastest Growing Region In Medical Suction Devices Market

The Asia Pacific region is expected to witness the fastest growth in the medical suction devices market during the forecast period. This is owing to surging geriatric population, rising prevalence of respiratory diseases due to growing air pollution levels and changing lifestyle habits in countries like China and India. Additionally, governments are implementing new initiatives to modernize healthcare infrastructure and expand medical insurance coverage to larger population base. Leading manufacturers are also shifting production facilities and establishing regional headquarters to capitalize the high growth opportunities in Asia Pacific. Moreover, increasing medical expenditures, emergence of multi-specialty hospitals and clinics and availability of low-cost devices are fueling the demand. Hence, the large patient pool, growing healthcare awareness and improving access to services makes Asia Pacific the most promising emerging market for medical suction devices globally.

Get more insights on this topic: https://www.marketwebjournal.com/medical-suction-devices-market-is-estimated-to-witness-high-growth-owing-to-increased-adoption-of-battery-powered-portable-devices/

About Author:

Priya Pandey is a dynamic and passionate editor with over three years of expertise in content editing and proofreading. Holding a bachelor's degree in biotechnology, Priya has a knack for making the content engaging. Her diverse portfolio includes editing documents across different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. Priya's meticulous attention to detail and commitment to excellence make her an invaluable asset in the world of content creation and refinement. (LinkedIn - https://www.linkedin.com/in/priya-pandey-8417a8173/)

What Are The Key Data Covered In This Medical Suction Devices Market Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Medical Suction Devices Market's growth between 2024 and 2031.

:- Accurate calculation of the size of the Medical Suction Devices Market and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Medical Suction Devices Market Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Medical Suction Devices Market vendors

FAQ’s

Q.1 What are the main factors influencing the Medical Suction Devices Market?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Medical Suction Devices Market companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Medical Suction Devices Market’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[blog-site-for-market-research]

Medical Oxygen Concentrators Market is Rising Rapidly in Coming Years

Market Overview –

The medical oxygen concentrators market focuses on devices designed to deliver oxygen therapy to patients with respiratory conditions. These devices concentrate oxygen from ambient air, providing a continuous and reliable source of oxygen for patients who require supplemental oxygen therapy. The market includes stationary and portable oxygen concentrators, as well as accessories such as nasal cannulas, oxygen masks, and tubing.

The medical oxygen concentrators market is witnessing rapid growth, especially in the segment of portable oxygen compressors. With an increasing emphasis on home healthcare, there's a surge in demand for convenient, lightweight concentrators. These portable devices offer patients greater mobility and independence while ensuring continuous oxygen therapy. This trend fuels market expansion and innovation in portable oxygen compressor technology.

The medical oxygen concentrators market was valued at USD 1.15 billion in 2021 and is expected to rise from USD 1.37 billion in 2022 to USD 4.80 billion by 2030, with a compound annual growth rate (CAGR) of 5.90% during the forecast period (2022- 2030).

Advancements in technology have led to the development of more efficient, lightweight, and portable oxygen concentrators, offering greater mobility and flexibility for patients. These devices allow patients to maintain their oxygen therapy regimen while engaging in daily activities, traveling, or receiving care in non-hospital settings.

The COVID-19 pandemic has underscored the importance of medical oxygen concentrators in managing respiratory complications associated with severe COVID-19 infection. The pandemic has led to increased demand for oxygen therapy devices, particularly in regions experiencing surges in COVID-19 cases, prompting healthcare facilities to invest in additional equipment and expand their oxygen supply capacity.

Market Drivers and Restraints

There has been an unusual increase in the demand for ventilators since the COVID-19 outbreak, leading to a considerable shortage worldwide. Ventilators’ unmet demand has compelled scientists and engineers to make makeshift ventilators with the use of respiratory equipment like oxygen concentrators, manual resuscitators, PAP, nebulizers, and more. This has been quite pivotal for the oxygen concentrators market, in terms of growth. Apart from the rising cases of SARS-CoV-2 despite the strict lockdown, COPDs/Chronic Obstructive Pulmonary Diseases have also surged significantly in recent years, which bolster the need for oxygen concentrators. Experts believe that despite the grave impact of the novel coronavirus and the rapid escalation of the pandemic, the global market can observe sustained growth due to the rise in technological innovations and the subsequent miniaturization of medical oxygen concentrators across the globe.

Governments and non-government agencies are proactively setting up programs and campaigns to make more citizens aware about asthma and COPD and the available treatment options. For example, NHLBI/National Heart, Lung, and Blood Institute along with WHO, created GOLD or Global Initiative for Chronic Obstructive Lung Disease to raise the awareness level regarding COPD. With the growing number of pandemics like SARS and COVID-19 in the past couple of years, the need for artificial or makeshift ventilators has soared, specifically for piped/canned and wall-mounted oxygen concentrators.

Furthermore, manufacturers are coming up with innovative technologies that aim to elevate the quality of healthcare. Companies are also entering agreements and collaborations to bolster their manufacturing capacity to meet with the soaring demand for oxygen concentrators in the global market. For instance, in October 2020, ZOLL Medical Corporation, a medical devices manufacturer, and CAIRE Inc., a renowned oxygen supply vendor, entered a distributor agreement. The agreement entails ZOLL getting the rights for the distribution of CAIRE’s SAROS 4000 Portable Oxygen Concentrators outside the United States.

Market Segmentation

Medical Oxygen Concentrators market can be split into product, technology, indication and end user.

The key products listed in the market study are stationary oxygen concentrators as well as portable oxygen concentrators. As of 2018, the portable oxygen concentrators segment has remained in the lead and can continue to do so throughout the given period due to the surging uptake by travelers as these are lightweight, compact, offer higher oxygen capacity and mobility. Stationary oxygen concentrators segment on the other hand, can record a better growth rate as these provide a relatively more stable oxygen source along with a hands-free provision as well as longer tubing.

Some of the top technologies considered in the study are continuous flow along with pulse dose.

Indication-wise, the market categories are sleep apnea, asthma, chronic obstructive pulmonary disease, and more.

The key market end users analyzed in the report include hospitals and clinics, travel, homecare, and others.

Regional Study

Medical oxygen concentrators market’s regional segmentation covers Europe, the Americas, MEA or Middle East & Africa and Asia Pacific or APAC.

Since 2018, the Americas has remained the highest revenue generating market, backed by the extensive spread of a large number of renowned companies and the availability of developed home healthcare care services. The mounting prevalence of respiratory diseases and the supportive reimbursement policies, especially in Canada and the US also bolster the revenue generation in the region. A case in point, studies by the Centers for Disease Control and Prevention reveal that at present; close to 16 million Americans suffer from chronic obstructive pulmonary disease. Besides, government led initiatives like the approval granted by Federal Aviation Administration (FAA) for the use of portable oxygen concentrators in flights prompt further market expansion in the region.

Europe is touted to be the second highest gainer in subsequent years, with the market value being significantly bolstered by the massive geriatric populace and the escalating cases of COPD, pulmonary hypertension, fibrosis and asthma. Rising exposure to aerosols, chemicals, smoke, and various pollutants has boosted the chances of developing respiratory diseases in the region. EMA/European Medicines Agency says that there are currently over 30 million asthmatic patients in Europe, which improves the chances of the medical oxygen concentrators market garnering a higher position in the region.

APAC can demonstrate the fastest growth between 2019 and 2024, on account of the heightened preference for portable concentrators among travellers, rising healthcare spending and the augmenting awareness level about advanced equipment like oxygen concentrators. The health and living standards across the emerging countries is improving at a stellar speed, which has enhanced the general life expectancy of the people. This has been a key booster for the elderly population in the region, which is prone to a number of diseases and thereby, elevates the need for medical oxygen concentrators.

Key Players –

Medical oxygen concentrators key companies include Invacare Corporation, Inogen Inc., Charted Industries Inc., Koninklijke Philips N.V., Drive DeVilbiss Healthcare, Medtronic plc, GCE Group, Nidek Medical Products Inc., ResMed, and Teijin Limited, among others.

Related Reports –

amniotic membrane market

asia pacific aesthetics market

diabetic nephropathy market

chronic kidney disease market

For more information visit at MarketResearchFuture

[legendaryturtletheorist]

Exploring the Frontiers of Science: Lung Cell Culture and its Implications in Research and Medicine

Introduction:

Lung cell culture, a sophisticated technique in cell biology, plays a pivotal role in advancing our understanding of respiratory diseases, drug development, and personalized medicine. This technique involves the extraction and cultivation of lung cells outside the body in a controlled environment, providing researchers with a powerful tool to study cellular processes, test new drugs, and develop innovative therapies. In this article, we will delve into the intricacies of lung cell culture, its applications, and the profound impact it has on scientific research and medical advancements.

Fundamentals of Lung Cell Culture:

Lung cell culture begins with the isolation of cells from lung tissues, either from animal models or human donors. The cells are then placed in a nutrient-rich medium that mimics the conditions found within the body. This artificial environment supports the cells' growth, allowing them to proliferate and form a monolayer or three-dimensional structures, depending on the research goals.

Primary cells, derived directly from tissues, and immortalized cell lines, which can divide indefinitely, are the two main types of cells used in lung cell culture. Primary cells are preferred when studying specific physiological processes, while immortalized cell lines provide a consistent and reproducible platform for large-scale experiments.

Applications of Lung Cell Culture:

Disease Modeling:

Lung cell culture has revolutionized the modeling of respiratory diseases such as asthma, chronic obstructive pulmonary disease (COPD), and lung cancer. By culturing cells from affected individuals or utilizing genetically modified cells, researchers can recreate disease conditions in vitro. This allows for the study of disease mechanisms, identification of potential therapeutic targets, and the development of more effective treatments.

Drug Discovery and Development:

The pharmaceutical industry heavily relies on lung cell culture for drug discovery and development. Testing potential drugs on cultured lung cells provides valuable insights into their efficacy, toxicity, and potential side effects. This step is crucial in the early stages of drug development, helping researchers identify promising candidates and eliminate those with unfavorable characteristics before moving to expensive and time-consuming clinical trials.

Infection Studies:

Lung cell culture is instrumental in studying respiratory infections caused by viruses, bacteria, and fungi. Researchers can infect cultured cells with pathogens to understand the host-pathogen interactions, immune responses, and the development of antiviral or antibacterial therapies. This approach has been particularly valuable in the study of respiratory viruses such as influenza and the coronavirus.

Toxicology Studies:

Evaluating the toxic effects of various substances on lung cells is another important application. Researchers can expose cultured cells to pollutants, chemicals, or other environmental factors to assess their impact on cellular function and viability. This information is crucial for understanding the potential risks associated with exposure to different substances and for establishing safety guidelines.

Stem Cell Research:

Lung cell culture is also integral to stem cell research aimed at regenerative medicine. By manipulating stem cells in culture, researchers can guide their differentiation into specific lung cell types. This approach holds promise for repairing damaged lung tissue and developing cell-based therapies for conditions like pulmonary fibrosis.

Challenges and Future Directions:

While lung cell culture has significantly advanced our understanding of respiratory biology, it comes with its own set of challenges. Culturing cells in an artificial environment may not fully replicate the complex interactions and conditions present in the human body. Researchers continually strive to improve culture systems to better mimic in vivo environments, incorporating factors like airflow, mechanical strain, and the three-dimensional architecture of lung tissue.

Moreover, the heterogeneity of lung cell populations adds another layer of complexity. Different cell types, including alveolar epithelial cells, bronchial epithelial cells, and immune cells, each have distinct characteristics. Researchers are working to develop more specialized culture techniques that account for this diversity, allowing for more precise and meaningful experiments.

As technology advances, lung cell culture is likely to become even more sophisticated. The integration of microfluidics, 3D bioprinting, and organ-on-a-chip technologies holds promise for creating in vitro models that closely resemble the complex structure and function of the human lung. These innovations could enhance the accuracy of drug testing, disease modeling, and toxicology studies, bringing us closer to personalized medicine tailored to individual patient profiles.

Conclusion:

Lung cell culture stands at the forefront of scientific and medical research, offering a versatile platform for studying respiratory diseases, testing drugs, and advancing regenerative medicine. Its applications extend across a spectrum of disciplines, from basic cellular biology to drug discovery and development. Despite the challenges, researchers continue to refine and innovate in the field, pushing the boundaries of what is possible.

As our understanding of lung cell biology deepens and technology continues to evolve, the impact of lung cell culture on healthcare and medicine is likely to expand. This technique holds the key to unlocking new insights into respiratory diseases, paving the way for more effective treatments and personalized therapeutic approaches.

[vaiswr]

Pulse Oximeter Market Size Worth USD 3,652.7 Million in 2030

The global pulse oximeter market size reached USD 2,100.6 Million in 2021 and is expected to register a revenue CAGR of 6.4% during the forecast period, according to the latest analysis by Emergen Research. Rising technological advancements along with increasing investments in medical devices are key factors driving market revenue growth. For instance, medical instrument companies are increasingly developing innovative and smart devices that incorporate a variety of sensors and simplify operational processes which are driving market revenue growth. Mitocon Biomed, a renowned company in the medical industry launched an India-made pulse oximeter called Oxysat. Respiratory diseases especially coronavirus is one of the major factors which recently increased the demand for pulse oximeters. Patients with low blood oxygen levels are prone to respiratory diseases such as Chronic Obstructive Pulmonary Disease (COPD) and Congenital Heart Disease (CHD). Mid-aged populations or individuals having health issues such as heart or lung diseases, and diabetes are at risk of severe COVID-19 infection are increasingly utilizing pulse oximeters to avoid hospital-acquired infections, thus driving market revenue growth.

[mexicodailypost]

Alert in Oaxaca due to nearly 400 deaths from pneumonia

Among the main causes are infection with the flu virus, pneumococcus and coronavirus The Health Services of Oaxaca announced that mainly the children and elderly population, as well as people with chronic diseases, such as diabetes, high blood pressure, asthma, chronic obstructive pulmonary disease (COPD), are the most affected. The pulmonologist assigned to the “Aurelio Valdivieso” civil…

[the-rachana]

Muscarinic Agonists Market - Revolutionizing Respiratory Care: Unleashing the Power of Muscarinic Agonists

Newark, New Castle, USA: The “Muscarinic Agonists Market” provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors

This latest report researches the industry structure, sales, revenue, price and gross margin. Major producers’ production locations, market shares, industry ranking and profiles are presented. The primary and secondary research is done in order to access up-to-date government regulations, market information and industry data. Data were collected from the Muscarinic Agonists manufacturers, distributors, end users, industry associations, governments’ industry bureaus, industry publications, industry experts, third party database, and our in-house databases.

Get a Free Sample PDF of the Report – https://www.growthplusreports.com/inquiry/request-sample/muscarinic-agonists-market/9006

Key Players in the Muscarinic Agonists Market: – 

Merck & Co. Inc.

Alcon Inc.

Novartis AG

Mantra Pharma Inc.

Chauvin Pharmaceuticals Ltd. 

Paladin Labs Inc.

Glenwood Inc.

Sun Pharmaceutical Industries Inc.

Daiichi Sankyo Company Ltd.

Cosette Pharmaceuticals Inc.

Methapharm Inc.

Panda Pharmaceuticals Inc.

Omega Laboratories Ltd.

Market Segmentation: 

GLOBAL MUSCARINIC AGONISTS MARKET - ANALYSIS & FORECAST, BY DRUG TYPE

Pilocarpine 

Bethanechol 

Methacholine

Others

GLOBAL MUSCARINIC AGONISTS MARKET - ANALYSIS & FORECAST, BY INDICATION

Ophthalmic Conditions (Glaucoma, Presbyopia, etc.)

Asthma

Chronic Obstructive Pulmonary Disease (COPD)

Bronchial Airway Hyperreactivity

Others (Schizophrenia, Alzheimer's Disease, etc.)

GLOBAL MUSCARINIC AGONISTS MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION

Oral

Ocular

Parenteral

Market segment by Region/Country including: –

-North America (United States, Canada and Mexico) -Europe (Germany, UK, France, Italy, Russia and Spain etc.) -Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.) -South America (Brazil, Argentina and Colombia etc.) -Middle East and Africa (South Africa, UAE and Saudi Arabia etc.)

This report also includes a discussion of the major players across each regional Muscarinic Agonists market. Further, it explains the major drivers and regional dynamics of the global Muscarinic Agonists market and current trends within the industry.

Request for customization in Report: https://www.growthplusreports.com/inquiry/customization/muscarinic-agonists-market/9006

Key Benefits for Industry Participants and Stakeholders One can find in-depth research data and industry trends of the Muscarinic Agonists Market Research. The report offers details on potential investment opportunities, including those that are local and sector-specific that may benefit stakeholders and members of the industry. One can gain a thorough grasp of market dynamics by looking at prices as well as the activities of producers and consumers. With the use of market research, which will assist in discovering and visualizing new market participants as well as their portfolios, will be better able to make decisions and create an efficient counter strategy to maximize market advantage.

COVID 19 Impact Analysis

The Muscarinic Agonists Market Research Reports include a thorough discussion of the coronavirus’s effects in addition to the major market trends. When considering the impact of the COVID-19 on the industry, insights, analysis, projections, and predictions are given in the report study.

Given the breadth of the pandemic’s disruption, it is evident that the current depression is fundamentally different from previous recessions. Due to the sudden drop in demand and growing unemployment, the business climate will alter. In this uncomfortable environment, businesses may carve new roads by embracing novel ideas like ”advance toward localization, cash conservation, supply chain resilience, and innovation.”

Muscarinic Agonists Market TOC: https://www.growthplusreports.com/report/toc/muscarinic-agonists-market/9006

the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

This report stays updated with novel technology integration, features, and the latest developments in the market

This report helps stakeholders to understand the COVID-19 and Russia-Ukraine War Influence on the Muscarinic Agonists industry.

This report helps stakeholders to gain insights into which regions to target globally

This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Muscarinic Agonists .

This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

QUICK BUY: https://www.growthplusreports.com/checkout-9006

Contact Us:

Manan Sethi Director, Market Insights Email: sales@growthplusreports.com Phone no: +1 888 550 5009 Web: https://www.growthplusreports.com/

About Us Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association). Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success. We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020."

[laocommunity]

Kamada's Groundbreaking Q1 2023 Financials: Reveals Surprising Growth and Unveils Exciting Plans for the Future

Kamada's Groundbreaking Q1 2023 Financials: Reveals Surprising Growth and Unveils Exciting Plans for the Future # Kamada's Groundbreaking Q1 2023 Financials: Reveals Surprising Growth and Unveils Exciting Plans for the Future # Introduction Investors and stakeholders have been eagerly waiting for Kamada's Q1 2023 financials, and the numbers have exceeded all expectations. The Israeli-based biopharmaceutical company has reported a significant increase in revenues and profits, impressing both the market and industry insiders. Along with the impressive financials, Kamada has also announced exciting plans for the future that will undoubtedly cement its position as a leader in the biopharmaceutical industry. This article will delve deeper into Kamada's groundbreaking Q1 2023 financials, including the surprising growth and upcoming projects that are sure to pique the interest of investors and pharmaceutical enthusiasts alike. Kamada's Growth Story Kamada's financials have proven to be more than impressive, with the company reporting revenue of $51.6 million, a solid 27% increase compared to the same quarter the previous year. What's even more impressive is the company's net profits of $6.5 million, up 125% from Q1 2022. This growth can be attributed to the success of Kamada's approved products, including the company's flagship product, Glassia®, a flagship treatment for alpha-1 antitrypsin deficiency. Kamada's innovative products have also contributed to this growth, including the company's investigational therapies, such as its plasma-derived immunoglobulin (IgG) for coronavirus. Kamada's earnings per share (EPS) have also exceeded expectations. The company's EPS came in at $0.19, a significant improvement from Q1 2022 when the EPS was just $0.08. Kamada's improving financials are a testament to the company's dedication to innovation, quality, and operational excellence. Kamada's Exciting Plans for the Future Kamada's impressive financials are not the only area the company is excelling. Kamada is committed to continuing the momentum through a series of exciting plans for the future. The Biopharmaceutical company has several ongoing projects related to the expansion of plasma-derived therapeutic products. One of the company's most notable ventures is the development of an inhalable Alpha 1-antitrypsin product for lung conditions such as Chronic Obstructive Pulmonary Disease (COPD). This product is expected to improve the lives of millions of patients worldwide. Additionally, Kamada is working on developing a high-concentration antithrombin product for patients requiring anticoagulant therapy. Kamada's management is also planning for the expansion of manufacturing capabilities and boosting research and development efforts to improve their biopharmaceutical portfolio. Kamada's Financials Impact on Investors Investors will undoubtedly be impressed by Kamada's recent financial performance, as the company's share prices have been skyrocketing. The company has seen a notable increase from $5 per share to $15 per share in the past year. Kamada's financial success, together with the long-term commitment to innovation and growth, has prompted investors to place higher value on their shares, marking the beginning of an exciting new chapter for the company. In addition to this financial success, Kamada expects its new products to be approved in the next few years, a development that will create even more significant financial opportunities for the company. It is a clear sign for investors that the biopharmaceutical sector is experiencing massive growth, and Kamada is leading the way. Frequently Asked Questions (FAQs) 1. What is Kamada? Ans: Kamada is a biopharmaceutical company that specializes in the development, production, and marketing of specialty plasma-derived protein therapeutics. 2. What is Kamada's flagship product? Ans: Kamada's flagship product is Glassia®, which is an FDA-approved treatment for Alpha-1 Antitrypsin Deficiency (AATD). 3. What does Kamada's Q1 2023 financial report reveal? Ans: Kamada's Q1 2023 financials revealed a 27% increase in revenues and a 125% increase in net profits compared to Q1 2022. The company's earnings per share (EPS) were $0.19 compared to $0.08 the previous year. 4. What are Kamada's future plans? Ans: Kamada's future plans include the expansion of their plasma-derived therapeutic products, including an inhalable Alpha 1-antitrypsin product for lung conditions and the development of a high-concentration antithrombin product. The company is also working on expanding their manufacturing capabilities and boosting research and development efforts. 5. Why is Kamada's financial success essential for investors? Ans: Kamada's financial success creates significant investment opportunities that enable investors to realize high returns from their investments. As Kamada continues to invest in new products, the company's market presence and revenue will continue to grow. 6. What is the significance of Kamada's financial performance to the biopharmaceutical industry? Ans: Kamada's financial success and growth are a reflection of the massive growth the biopharmaceutical industry is currently experiencing. It serves as an indicator of the opportunities available in the sector and illustrates that the application of innovation and operational excellence can lead to a high-return business model. Conclusion Kamada's Q1 2023 financials exceeded all expectations, and the company's revenue, net profits, and earnings per share have significantly improved in the past year. The financial performance coupled with Kamada's solid plans for growth are a clear sign that the company is on the path to becoming a leader in the biopharmaceutical industry. Investors and stakeholders can expect Kamada's share prices to continue to rise based on the company's success. Kamada serves as a model for innovation, dedication, and operational excellence, showing us that with the right approach, companies in the biopharmaceutical sector can be a win-win for investors and healthcare consumers. #NEWS Read the full article

[drnishthasingh]

Coronavirus and COPD - Dr. Nishtha Singh

Dr. Nishtha Singh is an experienced Chest Specialist and Pulmonologist in Jaipur at Asthma Bhawan with special interests in respiratory medicine, critical care, and sleep medicine. Dr. Nishtha Singh offers complete diagnostic and treatment of all Respiratory conditions, including Tuberculosis, Allergy, Asthma, Lung Cancer, and SLEEP APNEA. Make an appointment with the best doctor or call us: at +91 946 1685 766 and get more information. Read this article to know more about coronavirus and COPD.

[gaylordnantais]

Workers’ Compensation Lawyers for Occupational Diseases

Your life can change in an instant if you get hurt at work. If you or someone you care about got hurt at work, you might think you should talk to a lawyer. Because of your injuries, you may have to pay for medical bills, lose money and/or be unable to work. You may also worry about getting in trouble at work or losing your job. These benefits also cover work-related diseases and health problems, as long as they are caused by a person’s job duties or work surroundings.

Some Of The Most Common Occupational Diseases

Occupational disease are different from many other accidents protected by workers’ compensation because they are almost always caused by repeated contact with something harmful at work, not by a single event. The most common illnesses that can be caused by work are:

Skin conditions: Some skin diseases, like eczema, can be caused by direct contact with a dangerous chemical in an accident or spill, but most of the time, they are caused by tiny particles of an offensive substance over time. Cleaning products, chemicals, chemical-based solvents, and products like gelatin can cause allergic reactions.

Respiratory problems: People who work in places where there are pollutants or gases in the air often get respiratory illnesses and other breathing problems. Asthma and chronic obstructive lung disease (COPD) are two conditions that can happen. People working in construction, farms, mines or power industries are especially at risk.

Hear and eyesight loss: Employees who work in places with bright lights, loud noises, and other things that strain the eyes and ears may lose their vision and hear over time. Some toxic chemicals can also make it hard to see or hear.

Infectious diseases: Because they work with patients, health care workers are frequently at risk of getting a disease that can spread. Some of the most common viral infections in workers’ compensation cases are TB, hepatitis B and C, and HIV. During the COVID-19 pandemic, workers in any industry who get the coronavirus at work may also be qualified for workers’ compensation benefits.

Mental health problems: Workers’ compensation may pay for some mental health problems, especially if they are caused by a traumatic accident at work. Depression, worry, and post-traumatic stress disorder (PTSD) are all examples.

Cancer: Some workers are exposed to carcinogens, which can cause cancer, even if they are only in small amounts at work. Mesothelioma is a common type of cancer that can be caused by work. It is caused by contact with asbestos, which construction and building workers often do. Cancer of the lungs, skin cancer, and cancer of the bladder are also often linked to how a person works.

Conclusion

If you have an occupational disease, you need to talk to a skilled Workers’ Compensation Lawyer who can help you file a claim. We have a lot of experience handling cases for a wide range of occupational diseases at Gaylord and Nantais. We are here to help you get the right amount of pay. Give Workers’ Compensation Lawyer call at (562) 561-2669 to set up a free appointment.

[gilsoulassociates-blog]

Disability Issues Brief

Introduction

The COVID-19 pandemic has changed our world in many ways. People with disabilities, people with chronic health conditions such as heart disease, lung disease, and diabetes, and people over the age 60, are at a higher risk of becoming infected and most likely to become seriously ill. Safety measures such as social distancing, stay at home orders, and the wearing of face masks or cloth face coverings are now part of our daily lives. For the purposes of this document, the term “face mask” will be used for both face masks and cloth face coverings.

Wearing a face mask is one important way to slow the spread of COVID-19. The Centers for Disease Control and Prevention (CDC) recommends wearing a face mask in public places like grocery stores and pharmacies, where it is hard to stay six feet apart from other people. [1] Several state and local governments are requiring the use of a face mask when in public spaces.

Wearing a face mask may be difficult for some people with a disability. State and local government agencies or private businesses that want customers to use a face mask may have questions and concerns. This fact sheet offers answers to questions about the issue of face mask policies, reasons why a person with a disability might not be able to wear a face mask, and the legal rights a person has under the Americans with Disabilities Act (ADA).

May a state or local government agency or business require customers to wear a face mask?

On March 11, 2020, the World Health Organization (WHO) declared COVID-19 as a pandemic.[2] The Centers for Disease Control and Prevention (CDC) notes that studies have shown that many people who do not have symptoms of COVID-19 can spread the virus to other people. Because it takes four to fourteen days for someone to show symptoms, they also may infect others without knowing it. [3] This means that the virus can be shared between people who are close to each other. For example, people who are speaking, coughing, or sneezing may spread the virus even if they do not have symptoms.[4] Therefore, the CDC recommends that people over age two wear a face mask in public where it can be hard to stay six feet apart from others.[5]

Based upon the CDC guidance, a business or government agency may require customers to wear a face mask to limit the spread of COVID-19. Guidance from the CDC is likely to change as the COVID-19 pandemic evolves. Therefore, private businesses and government agencies should follow the most current information on maintaining safety by reviewing the Centers for Disease Control and Prevention (CDC) Coronavirus (COVID-19) information.

Is there a reason a person might not be able to wear a face mask?

The CDC states that a person who has trouble breathing, is unconscious, incapacitated, or otherwise unable to remove the face mask without assistance should not wear a face mask or cloth face covering.[6]

Examples of a person with a disability who might not be able to wear a face mask

Individuals with asthma, chronic obstructive pulmonary disease (COPD), or other respiratory disabilities may not be able to wear a face mask because of difficulty in or impaired breathing. People with respiratory disabilities should consult their own medical professional for advice about using face masks. The CDC also states that anyone who has trouble breathing should not wear a face mask.[7]

People with post-traumatic stress disorder (PTSD), severe anxiety, or claustrophobia (an abnormal fear of being in enclosed or narrow places),[8] may feel afraid or terrified when wearing a face mask. These individuals may not be able to stay calm or function when wearing a face mask.

Some people with autism are sensitive to touch and texture. [9] Covering the nose and mouth with fabric can cause sensory overload, feelings of panic, and extreme anxiety.

A person who has cerebral palsy may have difficulty moving the small muscles in the hands, wrists, or fingers. Due to their limited mobility,  they may not be able to tie the strings or put the elastic loops of a face mask over the ears. This means that the individual may not be able to put on or remove a face mask without assistance.

A person who uses mouth control devices such as a sip and puff to operate a wheelchair or assistive technology, or uses their mouth or tongue to use assistive ventilators will be unable to wear a mask.

read more..

[ecardon1]

Hospital at Home-An Idea Whose time has Come

Long before fears of infection from the coronavirus made people wary, hospitals were often not the best place to be treated and recover. Awareness of the risks of infections and the debilitating impacts of hospital stays, particularly on patients who are frail, have cognitive impairments, or other vulnerabilities, prompted Johns Hopkins University, to establish the first hospital-at-home program in the United States 20 years ago.

The model, which offers people who would typically require hospitalization to treat problems such as acute pneumonia, dehydration, or exacerbations of conditions like heart failure or chronic obstructive pulmonary disease (COPD) the option of receiving acute-level care in their homes, has been one of the most studied health care delivery reforms.

In recent years, a handful of U.S. health systems have launched similar programs, either because their hospitals are operating at capacity and/or they’ve taken on financial risk for the total costs of patients’ care and thus benefit from delivering services in a lower-cost setting. The Veterans Health Administration, which controls both payment and care delivery, has funded its own hospital at home program as have some health systems that have their own health plans and/or substantial numbers of patients in accountable care organizations or managed care plans.  

Several startup companies now offer logistical support and technology to facilitate hospital-at-home programs, as well as help contracting with commercial payers. Broader spread, however, has been stymied by the fact that Medicare does not pay for acute services provided outside of hospitals for fee-for-service beneficiaries.

As in so many parts of health care, the COVID-19 pandemic has catalyzed change: not only has it created a clear rationale for avoiding hospitals when possible, it has prompted Medicare to allow providers to bill for acute treatments delivered in surgery centers, hotels, or other non-hospital facilities. Some are hoping waivers tied to the Hospital Without Walls initiative will open the door for Medicare to pay for acute care in homes, too.

Several large hospital systems have begun their own hospital at home programs:

Mount Sinai Health System (NY)- Mount Sinai Health System launched a hospital-at-home demonstration in 2014, funded by a $9.6 million grant from the Center for Medicare and Medicaid Innovation. Leaders were drawn to the model as a way to relieve pressure on their inpatient wards, which even before the pandemic were routinely filled beyond capacity.

After the three year Medicare funded project ended Mount Sinai in 2017 set up a joint venture with Contessa Health, a Nashville-based startup launched in 2015 whose founders sought to make home hospitalizations financially sustainable by contracting with health plans willing to pay for them, namely Medicare Advantage plans, Medicaid managed care plans, and commercial health plans.

Tufts Medical Center (MA)- Like Mount Sinai, Tufts Medical Center in Boston was bursting at the seams, pre-COVID-19; it routinely had to turn down requests to accept patients from other hospitals because no beds were free. To help expand access, leaders had begun partnership discussions with Medically Home, another hospital-at-home company founded in 2017 after eight years of research and development. 

Medically Home partners with its clients’ clinicians and also hires physicians and nurse practitioners, who work from a central hub from which they use remote monitoring, video, and other telehealth tools to oversee patients’ care. They confer with Tufts Medical Center’s attending physicians to make sure patients are good candidates for the program. Advanced practice providers, paramedics, nurses, phlebotomists, technicians, therapists, and other staff visit acutely ill patients in their homes, providing infusion, lab tests, imaging, nutrition, translation, and other services. 

Medically Home draws on its health system partners and community resources, including local paramedics and equipment suppliers, to build a virtual hospital. 

Home-based models that offer coordinated episodes of care — including for emergent, acute, and post-acute needs — could be of particular benefit to patients who have frequent emergency department visits or hospitalizations.

CMS’s Hospital Without Walls initiative could provide a means by which hospitals can provide some care in homes, but it’s unclear how long the waiver will remain in place. To qualify as acute care, hospital providers need to deliver home services themselves and must deliver a certain level of services (e.g., oxygen, durable medical equipment, radiology, and meals).

In the short term, spread of the model may depend on the course of the coronavirus and hospitals’ desires to prepare for potential surges. In the longer term, it may find broader interest if value-based payments gain broader traction.

Ed Cardon

EPC Search International LLC

470-345-0846

ed@epcsearchinternational.com

[globaldatacom]

Big pharma companies strengthen their position in digital health with recent deals

Advanced wellbeing innovations can be utilized across the drug esteem chain. For instance, advances, for example, applications and wearables are an indispensable piece of decentralized clinical preliminaries and are utilized for essential sign observing, gathering electronic clinical result evaluations, working with virtual encounters with agents, and checking investigational drug adherence. They can likewise be utilized to produce and gather computerized biomarkers, which are measures gathered by sensors implanted in associated devices.

For instance, mouthpieces can be utilized to identify voice biomarkers, fine coordinated movements can be tried by swiping and composing on touch screens, and electrocardiogram sensors in smartwatches can quantify pulse fluctuations to distinguish conditions like atrial fibrillation. In post-promoting settings, genuine proof created from computerized devices can give a superior comprehension of item bearableness and harmfulness profiles, give better bits of knowledge into drivers of adherence, empower remote observing of item security, and coordinate the patient experience into research. In deals and promoting, they can be utilized in 'past the pill' benefits and give drug adherence, remote observing, ongoing illness the board and choice help apparatuses for patients and medical devices industry (HCPs).

To carry out these innovations, pharma organizations regularly fashion associations and joint efforts with various advanced wellbeing organizations, be they virtual preliminary sellers, wearable innovation suppliers or versatile application and computerized helpful designers. Somewhat recently, be that as it may, there have been a few computerized wellbeing consolidation and securing (M&A) and value bargains by large pharma organizations.

Last month, it was declared that AstraZeneca expected to secure a stake worth up to £25m ($33m) in Huma, a UK-based organization whose stage upholds computerized 'emergency clinics at home' and supports decentralized clinical preliminaries. The stage consolidates prescient calculations, computerized biomarkers and true information to help 'proactive, prescient consideration and exploration'. Simultaneously, Huma will get AstraZeneca's Flabbergast, an illness the executives stage for asthma and cardiovascular breakdown patients. The two organizations likewise plan to accomplice to send off programming as a medical gadget buddy applications for cell phones, as well as speed up the reception of decentralized clinical preliminaries.

This month, it was reported that Pfizer Australia intends to gain ResApp Wellbeing for around A$100m ($75m). ResApp Wellbeing has created cell phone applications for the finding and the board of respiratory illnesses, like pneumonia, asthma, bronchiolitis and constant obstructive aspiratory sickness (COPD). The innovation utilizes man-made brainpower to analyze and gauge the seriousness of conditions utilizing a patient's hack. Two applications have been supported for promoting in Australia and Europe: ResAppDx can separate respiratory illnesses and can be utilized in telehealth, crisis division and essential consideration settings, while SleepCheck permits individuals to self-survey their gamble of rest apnoea.

ResApp as of late reported that the principal UK pilot of ResAppDx as a short term facility apparatus in the Dartford and Gravesham NHS Trust will begin this year. The organization has likewise fostered a cell phone based evaluating test for Coronavirus during the pandemic. Simultaneously, Pfizer and ResApp have consented to an innovative work (Research and development) organization into Coronavirus diagnostics, at first for a very long time with the choice to expand.

As a result of Coronavirus lockdown and social removing measures, there has been a flood popular for options in contrast to face to face mind, with numerous areas of computerized wellbeing flourishing like virtual preliminaries, telemedicine and distant patient checking. Thus, numerous advances that permit the remote observing of patients have tracked down a super durable spot in the conveyance of care, as the advantages to different partners have been demonstrated to impressive range. The pharma industry necessities to exploit this new time of medical care and should incorporate these innovations across its worth chain to help its clients. GlobalData expects further arrangement making movement other than customary organizations as pharma organizations hope to reinforce their computerized wellbeing contributions.

For more insights on the sub-sectors of M&A deals in the medical devices sector in Q3 2022, download a free report sample 

Scotland offers an optimal climate to preliminary these new innovations and strategies, with a concentrated organization of top notch colleges, expert establishments, and wellbeing specialists. This is undeniably upheld by the public qualities in information and high level tech, for example, man-made brainpower and AI, which are speeding up improvement courses of events of medicines.

Then, at that point, there is the financing support accessible. Associations with colleges permit organizations to apply for UK financing streams. Furthermore, Scottish colleges have a history of getting UK financing. Over the most recent five years, through the Biotechnology and Natural Sciences Exploration Gathering and Medical Exploration Board, 13% (£450m) of all UK financing has gone to colleges in Scotland.

[adriaanmeij]

Wat is waar over

Covid-19 vaccins

Steeds meer mensen verzetten zich tegen het beleid van de  overheid over Covid-19, soms met goede argumenten, soms verspreiden zij onjuiste of onvoldoende onderzochte informatie. Er is een ravijn tussen de informatie in nieuwe media en die in gevestigde media. We moeten blijven praten op basis van feiten en argumenten. “Zwijg niet langer, spreek tegen”, zegt Sigrid Kaag begin januari 2023 in haar Nieuwjaarsrede in een breder verband. Kaag is partijleider van D66 en minister van Financiën.

Met elkaar spreken. Daar is ook op het gebied van het coronavirus en de brede discussie erover alle reden toe. Om te communiceren, om dichter bij aspecten van de waarheid te komen.  Zouden we over 50 jaar weten dat je een pandemisch virus niet moet beschrijden met een mRNA vaccin voor alle 8 miljard wereldburgers van dan, maar door gezond te leven en te werken? Hebben de bestrijders van vaccineren of de voorstanders van selectief vaccineren gelijk en zit de gevestigde globale gezondheidszorg (WHO, overheden) ernaast om iedereen te vaccineren? Hoe gaan we om met Big Pharma?  Hangt de actuele oversterfte samen met bijwerkingen van vaccinatie? Het is een mijnenveld.

Redelijke krachten

Minister Sigrid Kaag is duidelijk. Zij vindt dat “rechts-extremisten en complot-populisten de democratie bedreigen, maar onze democratie is wel de beste en enige duurzame manier om onze verschillen vreedzaam te overbruggen”. “Als er over feiten en procedures geen overeenstemming meer is, sociale media het debat vergiftigen en politici hun achterbannen met leugens ophitsen, kan het iedere democratie gebeuren”, zegt zij.

Zij: “de voedingsbodem voor extremistisch handelen in Nederland is zorgwekkend vruchtbaar. Eén op de vijf Nederlanders gelooft in de complottheorie dat een kleine, geheime groep mensen stiekem alle belangrijke beslissingen in de wereldpolitiek neemt. Eén op de tien gelooft dat het coronavirus het gevolg is van heimelijke acties van een bepaalde overheid of organisatie. Het is een stroming die brede wetenschappelijke consensus ontkent, journalisten ontmenselijkt en rechters verdacht maakt. “Ik roep alle redelijke krachten op: zwijg niet langer. Sta op. Spreek tegen”.

Veranderen

Veranderen, zodanig wonen, werken en leven dat een pandemie niet meer met altijd risicodragende vaccins bestreden moet worden, is niet eenvoudig en zeer tijdrovend. Vijftig jaar geleden stond het klimaat en de uitstoot van schadelijke stoffen al op de agenda. Er gebeurde niets.

Een voor velen herkenbaar voorbeeld uit mijn leven illustreert dat.  In 1971 was ik redacteur bij het oude Elseviers Weekblad, weet je nog. Die krant met pagina’s zo groot als een voetbalveld. Het kostte wat moeite, maar ik kreeg erdoor om een interview te doen met Lenze Meinsma, de Friese arts die naam maakte als anti-rook dokter en vriendelijke klokkenluider. Erg enthousiast was de redactie, 9 mannen en 1 vrouw, niet. Zij rookten bijna allemaal, ok op de redactie. Meinsma overleed op 85-jarige leeftijd in 2008.

Ik heb dat interview helaas niet meer. Meinsma was een echte klokkenluider en iedereen hoorde hem. Toch veranderde niets in het rookgedrag, ook niet bij mij. Ik heb toen 7 jaar niet gerookt, tot 1979, maar begon er na mijn echtscheiding in 1979 weer mee en trouwde een kettingrookster, mijn grote liefde. Pas in 2015 stopte ik definitief met roken. Ik bedoel te zeggen: verandering is gigantisch moeilijk. Het kan lang duren voordat iets tot je doordringt, vooral als je verslaafd bent.

Behalve dat COPD begon op te spelen was de vriendelijke en bemoedigende benadering van mijn rookgedrag door de longverpleegkundige van mijn huisartsenpraktijk een belangrijke stimulans om het roken op te geven. Zij kleineerde mij niet, maar schetste mogelijkheden om rookvrij door het leven te gaan. Dat is gelukt en daarom leef ik acht jaar later nog met veel plezier. Ik bedoel te zeggen: verandering in leefstijl is mogelijk.

Ongezondheid

Nederland is verslaafd aan de gezondheidszorg en artsen staan machteloos. Bijna 2 miljoen mensen zijn verslaafd aan drugs, gokken, gamen, alcohol en tabak. Half Nederland heeft overgewicht en 15% heeft serieuze obesitas.  Artsen schrijven te veel antidepressiva voor. Dat was in 1999 al bekend en in 2018 niet opgelost. In de VS is het erger. Wetenschappers van de Washington University School of Medicine in Saint Louis schatten dat zo'n 67,6 miljoen mensen van 25 jaar of ouder in de Verenigde Staten lijden aan obesitas. Dat is 32% van alle 213 miljoen mensen die 25 jaar of ouder zijn.

Vaccineren

De concrete vraag die voorligt is of ik me, of u zich, wel of niet had moeten laten vaccineren en boosteren tegen Covid-19. Naast het gegeven dat ik vertrouwen heb in de Nederlandse gezondheidszorg, liet ik me een leven lang vaccineren tegen griep, malaria en andere infectieziekten die de Rijksoverheid aanbeveelt. Bovendien overleden in maart 2020 in 14 dagen twee naasten aan Covid-19. Maar vaccineren is NIET verplicht in Nederland. Bovendien denk ik dat zoveel mensen door onderliggend lijden zo kwetsbaar waren voor Covid-19 dat grootschalig vaccineren onvermijdelijk was. Ik zie uit naar de parlementaire enquête die onder meer hierop antwoord moet geven.

Een artikel in Epoch Health vindt dat je niet moet vaccineren als de voordelen niet meer opwegen tegen de nadelen. Maar dat kunnen leken zoals ik niet beoordelen. Sommige artsen willen Pfizer en Moderna vaccines terugtrekken tot diepgaand onafhankelijk nader onderzoek is gedaan naar de voor- en nadelen. Zij pleiten voor vrijgeven van veel meer informatie. Dat vind ik terecht.

Er zijn veel mensen tegen vaccineren tegen Covid-19. Voor mensen vanaf 60 jaar is de vaccinatiegraad voor de herhaalprik in het najaar van 2022 ten opzichte van de bevolking niet groter dan 60%. Van elke tien Nederlanders laten twéé zich niet vaccineren. Bijna de helft van hen vindt het niet erg dat anderen zich wel laten vaccineren. In mei 2021 was de bereidheid tot vaccineren 71% volgens het CBS. Als kijkt naar die CBS-cijfers lijkt het zo dat 5-10% van de bevolking geen voorstander van vaccineren is.

Anti-vaccers

Een deel van hen zijn actieve anti-vaccers die niet zelden fanatiek en evangeliserend zijn met rapporten die onvoldoende onderbouwd zijn. Je kunt niet steeds goed zien wie dergelijke studies financiert, hoe diepgaand en representatief studies zijn en of de samenvattingen corresponderen met onderliggen de statistieken. We weten dat de meeste medicijnen bijwerkingen hebben die vaak onschuldig zijn, maar dat ernstige bijwerkingen zoals myocarditis na een MRNA-vaccinatie zelden voorkomen. Het trombose en trombocytopenie syndroom (na vectorvaccinatie) is zeer zeldzaam (RIVM, 2022e), aldus het CBS.   Maar er zijn ook artikelen die de huidige oversterfte proberen toe te schrijven aan andere bijwerkingen van mRNA vaccines.

Vaccineren hielp

Ik denk dat het vaccin voorkwam dat veel  meer mensen op de IC kwamen of overleden. Maar we moeten het wel verder onderzoeken. Het CBS-onderzoek van eind juni 2022 zegt hierover: “Er zijn geen aanwijzingen op populatieniveau voor een verhoogd risico op overlijden na ontvangst van een COVID-19 vaccin. De geobserveerde verlaagde kans op niet-COVID-19 overlijden na vaccinatie dient door beperkingen aan de beschikbare data en het observationele karakter van de analyse voorzichtig geïnterpreteerd te worden”. Ook blijkt uit het onderzoek “dat in de periode januari 2021- januari 2022 de kans op overlijden aan COVID-19 zoals geregistreerd in het doodsoorzakenregister veel lager voor gevaccineerde personen is, dan voor ongevaccineerde personen.”

De controverse

Er zijn op internet intussen tal van platforms en blogs te vinden die zich afzetten tegen wat zij “Main stream media” noemen en tegen de gevestigde gezondheidszorg. Ik denk dat kranten zoals Trouw, NRC en De Volkskrant evenals gevestigde omroepen wel degelijk ingaan op vraagstukken. Misschien zijn de kritische platforms ook kritisch over CBS-onderzoek, dat ik vertrouw als onafhankelijk en zorgvuldig.

Zij zoeken nieuwe wegen om de werkelijkheid vorm en inhoud te geven. Het zijn uitgaven zoals De Nieuwe Wereld, Frontnieuws, BLCK.BX, The Expose, Daily Sceptic, Watals, De Dagelijkse Standaard, De Andere Krant, Jensen, Epoch Health, Stichting Vaccinvrij enzovoorts. Sommige zijn zeer activistisch en vaak ongenuanceerd tegen wat de gevestigde orde doet, anderen zoals Blck.bx en de Nieuwe Wereld, stellen zich meer genuanceerd op.

Dit patroon is normaal. Ook in de technologie en industrie zie je dat nieuwe producten en diensten, de “early adapters” zich afzetten tegen de gevestigde media om een beter profiel te krijgen. Het is in mijn observatie allerminst zo dat gevestigde media de argumenten van nieuwe media negeren, wat een veel gehoorde kritiek is. Gevestigde media zijn wel langzamer omdat zij, als het goed is, geen meningen poneren als feit, maar drievoudig controle onderzoek doen op de juistheid van stellingen. En dan vallen de meeste door de mand. Nieuwe media zullen veel moeite hebben zich een blijvende positie te verwerven in het media landschap. Daar zijn miljoenen investeringen voor nodig. Initiatieven in de vorige eeuw zoals Accent en De Krant op Zondag haalden het niet ondanks grote investeringen.

Bijvoorbeeld dodelijk

Enkele voorbeelden geven hierin meer inzicht. Frontnieuws  van 11 januari 2023 vindt dat wetenschappelijk onderzoek bewijst dat Covid-19 vaccins schadelijk en ondoeltreffend zijn. Dat kan echter niet afgeleid worden uit het aangevoerde CDC-onderzoek . Daaruit blijkt alleen maar dat je na vaccinatie toch besmet kunt raken. Dat wisten we al. Het RIVM stelt: “Je kunt na vaccinatie nog corona krijgen. De kans om ziek te worden door corona is kleiner, omdat je door vaccinatie beter beschermd bent”. 

Frontnieuws noemt ook een studie van de Universiteit van Oxford onder ziekenhuispersoneel in Vietnam. Het ging om 62 medewerkers gevaccineerd met AstraZeneca, en niet 900 zoals Frontnieuws stelt. Dat is de totale staf van het ziekenhuis. Uit het onderzoek blijkt alleen maar dat je na vaccinatie toch corona kunt krijgen, met soms ernstige bijwerkingen zoals longontsteking. Er blijkt niet uit dat vaccinatie niet werkt en dodelijk kan zijn, zoals Frontnieuws beweert.

Wat is waar?

Mensen hebben de waarheid niet in pacht. Ben jij de enige die het echt weet, het juiste inzicht heeft? Ik denk dat mensen bepaalde facetten van wat waar is kunnen inzien, doorvoelen en omschrijven en dat de waarheid een flonkerende diamant is met veel facetten die mensen niet kunnen zien. Daarom: blijf praten en discussiëren aan de keukentafel en vooral: luisteren.